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Abstract
Recruiting research participants based on genetic information generated about them in a prior
study is a potentially powerful way to study the functional significance of human genetic
variation. However, it also presents significant ethical challenges that, to date, have received only
minimal consideration. We convened a multi-disciplinary workshop to discuss key issues relevant
to the conduct and oversight of genotype-driven recruitment and to translate those considerations
into practical policy recommendations. Workshop participants were invited from around the U.S.,
and included genomic researchers and study coordinators, research participants, clinicians,
bioethics scholars, experts in human research protections, and government representatives.
Discussion was directed by experienced facilitators and informed by empirical data collected in a
national survey of IRB chairs and in-depth interviews with research participants in studies where
genotype-driven recontact occurred. A high degree of consensus was attained on the resulting 7
recommendations, which cover informed consent disclosures and choices, the process for how and
by whom participants are recontacted, the disclosure of individual genetic research results, and the
importance of tailoring approaches based on specific contextual factors. These recommendations
are intended to represent a balanced approach—protecting research participants, yet avoiding
overly restrictive policies that hinder advancement on important scientific questions.
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Introduction
Translating advances in genomics into robust knowledge about the structure and function of
the human genome represents an unprecedented opportunity for understanding health and
disease (Green and Guyer 2011). Genotype-driven research recruitment is a potentially
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powerful tool for facilitating this translation (McGuire and McGuire 2008). Using this
approach, investigators search genomic data generated about participants in an existing
study population to identify those who possess a gene variant of interest, and then contact
them to invite their participation in further research to better understand the functional
significance of that variant (Beskow et al. 2010).
This kind of “recruitment by genotype” eliminates the expensive and time-consuming step
of screening new populations to find individuals who have the variant of interest (Chulada et
al. 2008). However, it also presents ethical challenges. When genetic information generated
in one study is used as the basis for identifying and contacting participants about further
research, concerns more commonly associated with participation in genetic research are
shifted to the recruitment phase (Beskow et al. 2010). A central issue is the disclosure to
research participants of their individual genetic results from the first study as part of the
recruitment process for the second. There is a fundamental tension between disclosing
genetic research results that may be unwanted and/or preliminary and easily misinterpreted,
and leaving prospective participants uninformed about the purposes of the second study and
why they are eligible to participate (Beskow et al. 2010).
To date, there has been only minimal consideration of the ethical issues associated with
recontacting participants for the purpose of additional research recruitment and with
genotype-driven recruitment in particular. We therefore convened a multi-disciplinary
workshop to formulate recommendations to help investigators and institutional review
boards (IRBs) identify balanced approaches—those that protect research participants, yet
avoid overly restrictive policies that limit opportunities for those who would like to
participate and that hinder advancement on important scientific questions.
Workshop Overview
We held a 1.5-day workshop in May 2011 at Duke University to discuss key issues relevant
to the conduct and oversight of genotype-driven recruitment and to translate those
considerations into practical policy recommendations. This discussion was informed by
empirical data collected through a national survey of IRB chairs (Beskow et al. in press) and
in-depth interviews with research participants in six studies where genotype-driven recontact
occurred (Beskow et al. 2011; Cadigan et al. 2011; Namey and Beskow 2011; Tabor et al.
2011). A wide range of stakeholders were represented at the workshop, including
researchers, study coordinators, and participants from the six studies, as well as bioethics
scholars, IRB leaders, other genomic and biobank researchers, clinicians, and federal
officials engaged in issues related to human subjects research (see Acknowledgements).
The workshop began with brief presentations of the empirical data, followed by discussions
aimed at initiating reflection on four major topics (Table 1). We had identified and outlined
these topics in a framing document that was circulated prior to the workshop. Each topic
discussion started with a diverse panel of workshop participants (e.g., a researcher, clinician,
IRB member, and research participant), who commented briefly on the topic from their
perspective. These comments were followed by large-group discussion directed by
experienced facilitators. The second day began with a synthesis of the first day's discussion,
followed by further discussion of the major topics. We returned to points of potential
disagreement with the aim of reaching consensus among a majority of the group. Discussion
continued on each topic until no disagreement was voiced in response to facilitators'
summary of the group's position (including minority opinions where applicable).
The discussion was documented through audio-recording and detailed note-taking for use in
preparing this report. We invited all workshop participants to comment on an early draft,
and later circulated a revised version with a request for participants to let us know whether
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they generally agreed with the recommendations. One participant was constrained from
expressing a formal opinion due to her governmental position; among the 36 remaining
participants, 33 affirmed their agreement.
Recommendations
Recommendation 1. Researchers should disclose the possibility of future contact for
further research recruitment during the informed consent process for the initial study
Contact for the purpose of recruitment to additional research will occur with increasing
frequency, even in cases where researchers do not necessarily anticipate such contact.
For prospective participants, advance notice about this possibility is a demonstration of
respect; for some, such disclosures may be important to inform their decision about current
research participation (Beskow et al. 2011). Although studies have found that participants
often do not remember information disclosed during the consent process (Prentice et al.
2007) poor recall is a separate issue that is not unique to genotype-driven recruitment. It
should be addressed in other ways, rather than serving as a justification for not providing
appropriate disclosures. When genotype-driven recruitment is specifically anticipated, it is a
good idea to communicate this to prospective participants in simple language; otherwise,
somewhat less detailed disclosures about the bases for future research recruitment may
suffice (Box 1).
In the case of currently existing consent forms, silence regarding the possibility of recontact
for the purpose of research recruitment should not automatically rule out such contact.
Contacting individuals without advance notice to ask about their interest in further research
participation may be contrary to their preferences, but does not necessarily result in harm
(Beskow et al. 2006). They can choose to not respond, express disinterest at the outset, or
learn more about the research and then decide whether to take part (Beskow et al. 2004).
Thus, although up front disclosure about future research contact is highly preferable, lack of
such disclosure during the consent process for already ongoing research should not
inevitably foreclose the possibility (Beskow et al. in press).
Consent forms that directly state or imply that contact for recruitment will not occur are
more concerning. These kinds of statements should be avoided unless there is a specific
reason to include them, e.g., in situations where researchers are willing to rule out future
contact and making this promise aids recruitment. Workshop participants agreed that, when
such statements have been included, there should be a strong presumption they will be
honored. A minority felt that further contact might still be permitted in limited situations,
based on compelling scientific justification and the use of a carefully designed approach.
Recommendation 2. Researchers should consider offering participants a choice at the
time of initial consent about future contact for further research recruitment
Giving participants a choice about whether researchers can contact them for recruitment to
additional research is not ethically required. For some studies, contact about additional
research is central to the research design and thus cannot be optional. However, when
feasible to do so, offering a choice at the time of initial consent would enable prospective
participants who do not want such contact to opt out and yet still participate in the
immediate study (Beskow et al. 2011).
Several ethical and logistical concerns have been raised about offering choices on consent
forms in general (Ram 2008), including whether participants can be given enough
information to make an informed selection at the time of initial consent (Beskow and Burke
2010). However, willingness to be contacted about future research can be presented as a
Beskow et al. Page 3













simple binary (yes/no) choice about which we believe participants can be given enough
information—assuming that the options and their implications are adequately explained.
If choices about future research contact are offered during the initial consent process,
systems must be in place to ensure that each participant's decisions are tracked and honored
(http://biospecimens.cancer.gov/bestpractices/2011-NCIBestPractices.pdf). If choices are
not offered, researchers should be prepared to follow wishes that are expressed later, e.g., if
a participant responds to contact about additional research by stating the desire to opt-out of
any more contact.
Recommendation 3. Contact about additional research should be made by a person or
entity known to the participant
Genotype-driven recruitment could be undertaken by investigators who want to recontact
selected participants in their own studies about additional research (Beskow et al. 2010).
However, investigators other than those who originally interacted with the participants may
also seek to use genotype-driven recontact.
Prospective participants should not be left wondering how investigators obtained
information about them (Beskow et al. 2004). It is therefore preferable that initial contact
about further research be made by a trusted intermediary—either the original research team
or the entity through which the person was originally recruited.
We recognize that this recommendation would pose non-trivial challenges if genotype-
driven recruitment was permitted based on searches across multiple data sets stored in
centralized repositories (such as the National Institutes of Health's database of Genotypes
and Phenotypes, dbGaP (http://gwas.nih.gov/02dr2.html). McGuire and McGuire (2008)
have suggested that using data shared through centralized repositories for such recruitment
could maximize the utility of the massive amounts of information generated in genomic
studies. Our recommendation, however, would not create additional barriers given that
database users currently have no access to identifying information without working through
the original investigators. Even if these databases were re-structured to allow more direct
access (a topic not discussed at our workshop), close control and monitoring of recontacts
would be vital to promote participant trust and long-term sustainability. At a minimum,
recontact must include a clear explanation of how and where those conducting the new study
obtained prospective participants' names—ideally referencing a source that is readily
recognizable to participants. This process would be vastly enhanced by comprehensive
efforts to educate research participants and the public about large-scale data sharing.
Recommendation 4. The process for contacting participants about additional research
should be designed based on a range of considerations related to the research team and
study question
The logistical process by which participants are contacted about additional research should
be designed based on a range of contextual considerations. Factors that might warrant a
more cautious approach include:
• Research conducted by different investigators than those who originally interacted
with participants;
• Research focused on a different medical condition than the one for which
participants were originally recruited; and/or
• Research focused on a potentially sensitive or stigmatizing issue (even if this issue
is the same as that originally under study, some participants may be averse to being
asked repeatedly, or by different investigators, about a difficult subject).
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These factors do not necessarily preclude recontact, but may favor a more conservative
process, such as requiring an opt-in approach (i.e., the research team talks about the study
with only those people who, in response to an initial letter, opt in to learning more) rather
than allowing an opt-out approach (i.e., the research team follows up with all prospective
participants except those who respond to an initial letter by opting out of further
communication).
One situation that may preclude contact about additional research is that in which
individuals who are eligible for a genotype-driven study never provided informed consent
for genomic research. For example, research using biospecimens left over from a clinical
procedure sometimes proceeds based on the protocol being exempt from human subjects
regulations or with a waiver of the requirement to obtain informed consent (45 CFR
§46.101(b)(4), 45 CFR §46.116(d)).
Workshop participants agreed that contacting individuals who may have no awareness of
having been involved in research, based on something learned from that research, is fraught
with difficulty. It may be perceived as an invasion of privacy and undermine trust in
research and in the health care entity that collected the specimens. A minority, however, felt
that such contact may be acceptable in rare cases. Moving forward with genotype-driven
recruitment in such circumstances would require thorough consideration of the importance
of the scientific questions and the unique nature of the study population, as well as the
development and close oversight of an exacting approach.
It is important to distinguish between ‘never having provided informed consent’ and much
current biobanking research where participants do provide informed consent for the storage
and research use of their biospecimens and data (even though they do not provide specific
consent for each subsequent use of their stored materials). In the latter instance, individuals
can be informed during the initial consent process about the possibility of future contact.
Recommendation 5. Thresholds established for the return of individual genetic research
results in general should not be used for decision-making about return of results in the
context of genotype-driven recruitment
The general topic of return of individual results to participants in genomic research is the
subject of vigorous ongoing debate. Opinions range widely from the view that such results
should seldom if ever be offered (Meltzer 2006; Miller et al. 2008; Parker 2006) to the view
that they should be offered routinely (Fernandez 2008; Kohane and Taylor 2010; Shalowitz
and Miller 2005). National entities have issued guidelines placing the bar for disclosure at
clinical validity and utility (Fabsitz et al. 2010; NBAC 1999), i.e., results should be offered
only when a proven therapeutic or preventive intervention is available. Many consent forms
for genomic research contain statements either conforming to this high bar or simply noting
that no individual results will be returned.
Decisions about return of results in the context of genotype-driven recruitment should not be
bound by these kinds of consent disclosures. Such statements reflect thresholds established
for offering research results for the participant's personal or health-related benefit. In
contrast, offering individual results during the process of genotype-driven recruitment is
motivated by the need to ethically achieve a scientific goal. These are fundamentally
different objectives.
Clinical validity and utility is a standard that would rarely be met in the context of genotype-
driven recruitment, where further research is needed specifically because more must be
learned to decipher the meaning of genetic research results in terms of risk, inheritance,
diagnosis, prognosis, and treatment (Beskow et al. 2010). If this threshold were
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automatically applied, it would nearly always result in the need to obfuscate the purpose of
the follow-up study and the reason why certain participants are being recontacted. A lower
threshold—allowing for more preliminary results to be offered—should be considered for
decision-making with regard to genotype-driven recruitment.
Recommendation 6. In most cases, individual genetic research results should be offered
in the context of genotype-driven recruitment. A careful series of steps should be used
both to avoid leaving prospective participants uninformed about the purpose of the study
and to maximize their right not to know unwanted genetic information
Because of the ethical importance of avoiding deception when explaining the purpose of a
genotype-driven study and why prospective participants are eligible, we believe it will be
appropriate to offer individual genetic research results in most cases. It is crucial, however,
that information be carefully and incrementally revealed in order to preserve prospective
participants' right not to know unwanted genetic results (Andorno 2004; Laurie 1999).
Specifically, enough information must be given to enable individuals to decide whether to
learn more about the research, without disclosing or implying their results prior to their
agreement to receive such information.
Figure 1 depicts one such approach. A key starting component for many studies will be the
communication of aggregate results in clear lay language, conveying the nature and
limitations of the original research findings. The description of the follow-up study should
be given at a general enough level that prospective participants can understand the broad
premise of the study, but cannot directly infer their individual status with regard to genetic
inclusion criteria. At each stage, the information previously discussed should be reviewed
and the prospective participant's desire to proceed confirmed. It is critical that people
understand the tenuousness of the results they receive, and the use of well-trained research
staff is essential.
Our recommendation that individual results should generally be offered in the context of
genotype-driven recruitment is not intended to suggest that they must be offered in every
instance. For each study, arguments both for and against offering results will have to be
considered (see Recommendation 7). In addition, the decision to receive results must be
made by the potential recipient. Researchers and IRBs should determine in advance whether
individuals who do not want to know their results can still participate in a genotype-driven
study. Some individuals may wish to contribute to scientific advancement on the study
question without knowing their status; if this is deemed acceptable from an ethical and
scientific perspective, processes must be in place to avoid inadvertent disclosure during the
course of the study.
The role of the Clinical Laboratory Improvement Amendments (CLIA) in the disclosure of
research results is an important topic but our workshop was not constituted to meaningfully
address this regulatory issue. CLIA certification is required of laboratories that report
patient-specific results “for the purpose of providing information for the diagnosis,
prevention, treatment of disease, or impairment of, or assessment of health” (https://
www.cms.gov/CLIA/). Discussion continues regarding whether research labs that are not
CLIA certified can disclose any information to participants (Fabsitz et al. 2010; Wolf et al.
2012; Wolf et al. 2008). However, we believe the explicit motivation for offering results in
the context of genotype-driven recruitment—to achieve a scientific goal in an ethical
manner, not for the participant's health-related benefit—is highly pertinent to this issue and
merits further exploration.
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Recommendation 7. For each study, appropriate approaches to genotype-driven recontact
and the disclosure of individual genetic research results should be determined by
researchers in consultation with their IRB
Empirical research suggests there is unlikely to be a “one-size-fits-all” solution, but rather
several ethically acceptable approaches to genotype-driven recruitment depending on
context (Beskow et al. 2011; Beskow et al. in press). For each study, the logistical process of
recontact and the decision about whether to offer individual genetic results should be
determined by researchers in consultation with their IRBs. Several factors, in addition to
those already discussed, should be considered, including:
• The nature of the researcher-participant relationship, including the frequency and
duration of interactions, the longevity of the relationship, and whether the
researcher is also the participants' physician or is part of the entity that provides
participants' health care (Beskow and Burke 2010)
• The nature of the research findings, including whether they are related to the
etiology of an already-diagnosed condition (Namey and Beskow 2011) or suggest
something about future risk or prognosis (per Recommendation 6, thresholds of
validity and utility may be lower than those recommended for the return of results
in general, but the research findings' certainty and usefulness (or lack thereof)
should be considered when designing appropriate approaches to genotype-driven
recruitment)
• The nature of the study population, including whether or not participants have been
diagnosed with the condition under study (Cadigan et al. 2011), whether
participants are minors (Tabor et al. 2011), and issues related to cognitive, social,
psychological, or economic vulnerabilities (Beskow and Burke 2010)
• The nature of the follow-up study design, including plans to recruit family
members (Beskow et al. 2004; Beskow et al. 2010; Hull et al. 2004)
In particular, investigators and IRBs should be aware of the range of expectations and
assumptions that prospective participants may hold with regard to the meaning and
usefulness of genetic information, and tailor their plans accordingly (Cadigan et al. 2011;
Namey and Beskow 2011; Tabor et al. 2011). For instance, participants who have a
condition without clear etiology may expect that genetic research results will reveal the
cause of their illness (Namey and Beskow 2011). With awareness of the potential for this
kind of over-interpretation, investigators can devise approaches to genotype-driven
recruitment that include easy-to-understand explanations of the state of genomic science in
their area of research, what the results of a particular study do and do not mean, and what
they hope to learn with further study. There are several resources for identifying likely
expectations among the target study population, including clinicians who regularly treat
patients with the condition under study, disease advocacy organizations, or even a simple
focus group of potential participants (Namey and Beskow 2011).
Conclusion and Future Directions
In their vision for the future of genomic research and the path toward genomic medicine,
Green and colleagues stated (Green and Guyer 2011),
…large-scale genomic studies alone will not be sufficient for gaining a
fundamental understanding of biology. Most of the data analysis and interpretation
will actually come from individual research efforts. Indeed, a primary motivation
for the development of genomics … has been to generate data catalogues and
technological tools that empower individual investigators to pursue more effective
hypothesis-driven research. (p.207)
Beskow et al. Page 7













Genotype-driven recruitment is a potentially powerful approach to such research—a means
to advance the pace of research on the functional significance of human genetic variation
and speed progress toward the ultimate goal of benefitting human health (McGuire and
McGuire 2008). At the same time, this kind of recruitment raises concerns because the
potential harms associated with the use and disclosure of genetic information are linked to
the offer to participate in research.
Our recommendations address some issues that are generic with respect to recontacting
participants about additional research as well as special issues that arise in genotype-driven
recruitment. They are based in part on empirical data and should themselves be the subject
of additional research. They are also based on current regulations for the protection of
human research participants, which may undergo significant change (Emanuel and Menikoff
2011). As the landscape continues to evolve, it will be important to examine awareness and
uptake of these recommendations, and to assess the outcomes of their implementation in
terms of the impact on research participants and on rates of participation in scientifically
valuable research.
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Figure 1. Sample Approach to Genotype-Driven Recontact and Recruitment
* In a biobank context, this point could be expanded to include (a) a reminder of biobank
participation, and (b) a brief description of the specific study, e.g., “One of the studies
researchers did with the stored samples and data was to look for links between X and Y.”
Readability characteristics: STEP 1 - Flesch-Kincaid grade level 7.3, Flesch-Kincaid reading
ease 73, passive sentences 7%; STEP 2 (vary depending on which bulleted sentence is used)
- Flesch-Kincaid grade level 7.7-8.8, Flesch-Kincaid reading ease 62-71, passive sentences
0%; STEP 3 - Flesch-Kincaid grade level 9.2, Flesch-Kincaid reading ease 60, passive
sentences 0%
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